Biodesix (BDSX) The 44th Annual William Blair Growth Stock Conference summary

Business performance and growth

• Achieved seven consecutive quarters of over 50% growth and industry-leading gross margins at 79%.

• Recent $55 million fundraise is intended to be the last before reaching profitability, supporting commercial team expansion from 60 to 85 reps by year-end.

• Sales reps are fully integrated, with new hires historically paying for themselves within three months.

• Productivity per sales rep is $1–$1.25 million annually, with territory adjustments to boost efficiency.

• New 80,000-square-foot facility enables growth for the next decade without major capital investment.

Product portfolio and innovation

• Five on-market blood-based lung cancer diagnostic tests, all with Medicare and private payer coverage.

• Two Nodify tests, launched in Q1 2022, are primary growth drivers with first-mover advantage and no competition until at least 2028.

• Three additional pipeline tests are in research-use-only phase, including unique pre-surgical recurrence and immune response tests.

• Partnership with Memorial Sloan Kettering and Bio-Rad to introduce a Minimal Residual Disease (MRD) test.

• All tests feature rapid turnaround times, with some results available within 24 hours.

Market opportunity and strategy

• Focused on lung cancer, the deadliest cancer, with 5 million annual candidates for nodule risk assessment.

• Commercial team targets 14,000+ pulmonologists, aiming for deeper market penetration.

• 60% of lung cancer patients are over 60, aligning with Medicare-heavy coverage and strong margins.

• Execution play centers on expanding sales force and embedding reps for consultative selling.

• National accounts team works with payers and networks to drive top-down adoption.